Cara Therapeutics is crashing on mixed trial results for a pain treatment, just after positive news on a liver disease drug powered the stock some 50% higher last …
source CNBC
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More